CRH (CRH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Executive summary
Record 2025 financial results: revenues up 5% to $37.4B, net income up 8% to $3.8B, Adjusted EBITDA up 11% to $7.7B, and diluted EPS up 10% to $5.51.
Total Shareholder Return for 2025 was 36.8%, with share price rising from $92.52 to $124.80.
$4.1B invested in 38 acquisitions, including $2.1B for Eco Material Technologies, and $1.7B in growth capex.
Continued long-term dividend growth policy; 2025 dividend increased 6% to $1.48 per share.
Announced intention to delist from LSE and cancel legacy Preference Shares, subject to shareholder approval.
Voting matters and shareholder proposals
12 proposals at 2026 AGM: re-election of 12 directors, advisory vote on executive compensation, auditor appointment and compensation, renewal of authorities to issue shares, repurchase shares, re-issue treasury shares, and several proposals related to Preference Share cancellations and amendments to Articles.
Preference Share cancellations involve court-approved schemes, capital reduction, and amendments to Articles.
Shareholders to vote on removal of director qualification shareholding requirement.
Board of directors and corporate governance
Board comprises 12 directors, 92% independent, with diverse skills in industry, finance, M&A, governance, and sustainability.
Annual board and committee evaluations, with external facilitation in 2025.
Board succession planning and refreshment are ongoing priorities.
Five standing committees: Audit, Compensation, Nomination & Corporate Governance, Acquisitions/Divestments & Finance, and Safety/Environment/Social Responsibility.
Latest events from CRH
- Strong organic profit growth and cash generation cut year-end net debt below 3x EBITDA.CRH
H2 2015 - Strong growth and cash generation cut leverage to 1.7x while supporting further growth.CRH
H2 2016 - €3.3bn EBITDA, stronger margins and returns, and major acquisitions positioned for further growth.CRH
H2 2017 - U.S. momentum and cost actions supported 2013 progress as net debt fell EUR 519m.CRH
H2 2012 - H2 momentum improved as portfolio actions and disciplined investment set up a moderate 2014 recovery.CRH
H2 2013 - EBITDA rose 11% in 2014; 2015 priorities were growth, integration and debt reduction.CRH
H2 2014 - Sales rose 5% and EBITDA reached €1.66bn as margins proved resilient.CRH
H2 2011 - Cash discipline and cost savings steadied results as markets began to stabilize.CRH
H2 2010 - Q3 EBITDA held near prior year; FY26 guidance is $7.8B–$8.0B amid cost and residential headwinds.CRH
Q3 2026 - Q2 2026 saw strong growth, margin gains, and the Arcosa deal, supporting a positive outlook.CRH
Q2 2026